Multiplexed Molecular Diagnostics Market by Technologies, Applications, End Users, Growth Trends and Forecast to 2021, Upcoming Report by iHealthcareAnalyst, Inc.

Multiplexed Molecular Diagnostics Market by Technology (Low Density Multiplexed Assays, Medium Density Multiplexed Assays, High Density Multiplexed Assays, Very High Density Multiplexed Assays, Next Generation Sequencing Assays), Application (Allergies, Autoimmune Diseases, Cardiac Diseases, Infectious Disease Diagnostic, Oncology, Pregnancy & Fertility Testing), End Users (Academic Research Institutes, Clinical Research Organizations, Diagnostic Laboratories, Hospital, Pharmaceutical Companies)

Maryland Heights, MO, April 27, 2017 --(PR.com)-- The development and implementation of highly multiplex molecular diagnostic tests have allowed clinical microbiology laboratories to more rapidly and sensitively detect a variety of pathogens directly in clinical specimens. The industry with new molecular diagnostic (MDx) tests is significantly less costly, while simultaneously increasing the number of targets per test through high multiplexing. The advanced technology has the potential to drive growth in the market, particularly in areas such as infectious disease testing, genetic analysis, and personalized medicine. Validation of a large number of disease markers in both molecular and protein diagnostics has paved the way for the emergence of the multiplex assay. The simple low-throughput multiplex assays followed by low-level multiplexing and high-throughput array-based immunoassays are replaced with two types of high-level multiplexing and high-throughput diagnostic methods using microspot arrays and bead arrays. Benefits of using multiplex molecular diagnostics array platforms include improved-quality patient care, as well as cost effectiveness and time saving.

Browse Multiplexed Molecular Diagnostics Market by Technology (Low Density Multiplexed Assays, Medium Density Multiplexed Assays, High Density Multiplexed Assays, Very High Density Multiplexed Assays, Next Generation Sequencing Assays), Application (Allergies, Autoimmune Diseases, Cardiac Diseases, Infectious Disease Diagnostic, Oncology, Pregnancy & Fertility Testing), End Users (Academic Research Institutes, Clinical Research Organizations, Diagnostic Laboratories, Hospital, Pharmaceutical Companies) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/multiplex-molecular-diagnostics-market/

The global multiplexed molecular diagnostics market segmentation is based on technology (low density multiplexed assays, medium density multiplexed assays, high density multiplexed assays, very high density multiplexed assays, next generation sequencing assays), application (allergies, autoimmune diseases, cardiac diseases, infectious disease diagnostic, oncology, pregnancy & fertility testing), end users (academic research institutes, clinical research organizations, diagnostic laboratories, hospital, pharmaceutical companies).

The global multiplexed molecular diagnostics market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global multiplexed diagnostics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global multiplexed molecular diagnostics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global multiplexed molecular diagnostics market and profiled in this report include Abbott Laboratories, Agilent Technologies, bioMérieux SA, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Illumina, Inc., Luminex Corporation, Siemens Healthineers, and Thermo Fisher Scientific, Inc.

1. Technology
1.1. Low Density Multiplexed Assays (plex ≤ 5)
1.2. Medium Density Multiplexed Assays (plex < 500)
1.3. High Density Multiplexed Assays (500 ≤ plex ≤ 10,000)
1.4. Very High Density Multiplexed Assays (> 10,000-plex)
1.5. Next Generation Sequencing Assays

2. Application
2.1. Allergies
2.2. Autoimmune Diseases
2.3. Cardiac Diseases
2.4. Infectious Disease Diagnostic
2.5. Oncology
2.6. Pregnancy & Fertility Testing

3. End Users
3.1. Academic Research Institutes
3.2. Clinical Research Organizations
3.3. Diagnostic Laboratories
3.4. Hospital
3.5. Pharmaceutical Companies

4. Geography (Region, Country)
4.1. North America (U.S., Canada)
4.2. Latin America (Brazil, Mexico, Rest of LA)
4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
4.4. Asia Pacific (Japan, China, India, Rest of APAC)
4.5. Rest of the World

5. Company Profiles
5.1. Abbott Laboratories
5.2. Agilent Technologies
5.3. bioMérieux SA
5.4. Bio-Rad Laboratories, Inc.
5.5. F. Hoffmann-La Roche Ltd.
5.6. Hologic, Inc.
5.7. Illumina, Inc.
5.8. Luminex Corporation
5.9. Siemens Healthineers
5.10. Thermo Fisher Scientific, Inc.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/multiplex-molecular-diagnostics-market/

About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com

Website: https://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
ContactContact
Categories